Water retention, mild headache, and transient numbness/tingling have been reported with GH-elevating compounds
[1] [3] Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist with similar clinical effects
CJC-1295 is an analog of growth hormone-releasing hormone, but its modified with a longer half-life for sustained growth hormone release.2 Meanwhile, ipamorelin mimics ghrelin but operates selectively so that it targets only growth hormone release, having no impact on other hormones (e.g., cortisol) that similar peptides often affect.3 4 Together, they allow your body to produce more growth hormone more often, thus facilitating muscle growth and fat loss over an extended period.5 Because of their complementary time-release characteristics, theyre commonly used together
So here is my reductionist representation
Tirzepatide delivered more than double that in its mid-range dose and nearly triple it at the highest dose
Comparison with observational cohort data The deCODE study measured 4,907 protein targets in 35,559 Icelanders with the SomaScan v4.0 multiplex aptamer assay and examined the association between plasma protein levels and 373 clinical phenotypes after adjusting for age, sex and multiplicity 23
